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ABSTRACT 
Background and aims: Obesity has become the sixth most important risk factor 
contributing to the overall burden of a variety of diseases worldwide. The 
association of anthropometric measures of obesity with mortality from various 
causes and incidence of cancers of various sites has been investigated, but it 
remains controversial. The aims of this study were to: 1) evaluate the 
epidemiological nature of the association of anthropometric measures of obesity 
with mortality from various causes, and to detect a potential threshold in this 
association; 2) study the epidemiological nature of the association between body 
mass index and incidence of cancer of different sites, and to detect a potential 
threshold in the association; 3) compare the strengths of different anthropometric 
measures of obesity in relation to cardiovascular disease (CVD) mortality; 4) assess 
the risk of CVD mortality in relation to obesity and sex in the general population, 
and also separately for those with or without diabetes at baseline.  
Study population and Methods: This study was based on data subsets of the 
Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe 
(DECODE) study and the National FINRISK study, including 72 947 European 
men and 62 798 women (I), 26 636 Finnish men and 28 089 women (II), 24 686 
European men and 21 965 women (III/IV), and 23 629 European men and 21 965 
women (V) aged 24 years or above at baseline. Hazard ratios (HRs) corresponding 
to categorical or continuous body mass index (BMI), waist circumference (WC), 
waist-to-hip ratio (WHR), waist-to-height ratio (WHtR) or waist-to-stature ratio 
(WSR), a body shape index (ABSI) and waist-to-hip-to-height ratio (WHHR) were 
estimated by the Cox proportional hazards model adjusting for several potential 
confounding factors measured at baseline. The non-parametric smooth functions of 
several anthropometric measures of obesity were fitted to health outcomes in order 
to explore the potential curvilinear relationship using the spline regression model, 
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with a threshold detected by a piecewise regression model (II/III). HR per standard 
deviation increment of each anthropometric measure of obesity in relation to CVD 
mortality was compared using the paired homogeneity test (IV).  
Results: BMI, WC and WHtR had a U- or J-shaped relationship with all-cause 
mortality (I/III), whereas WHR, ABSI and WHHR had a linear positive 
relationship with all-cause mortality (III). BMI had a J-shaped relationship with 
CVD mortality (I/III), whereas anthropometric measures of abdominal obesity 
(WC, WHR, WHtR and ABSI) had a linear positive relationship with CVD 
mortality (III). BMI had a U-shaped relationship with cancer mortality in both 
men and women but disappeared among non-smokers, which showed no 
association (I). BMI had a linear positive association with incidence of cancers of 
the colon, liver, kidney, bladder and all sites combined in men, and of cancers of 
the stomach, colon, gallbladder and ovary in women, an inverse association with 
incidence of cancers of the lung in men and the lung and breast in women, and a J-
shaped association with incidence of all cancers combined in women (II).  
  A one-standard-deviation increase in all obesity indicators were significantly 
associated with a more than 19% increase of CVD mortality risk in both men and 
women, and the prediction for CVD mortality was stronger with anthropometric 
measures of abdominal obesity than that with BMI and ABSI, and most strongly 
with the WHtR/WSR (IV). Men had higher CVD mortality rates and higher HRs 
across BMI categories, and categories of abdominal obesity than women (V). The 
sex difference in CVD mortality was slightly smaller in obese than in non-obese 
individuals; the negative interactions were statistically significant between sex and 
WC (p =0.02), and sex and WHtR (p =0.01). None of the interaction terms was 
significant when the analyses were carried out among non-diabetic or diabetic 
individuals separately (V).  
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Conclusions: This study confirmed the deleterious effect of obesity on mortality 
from various causes and incidence of cancers of certain sites. The prediction for 
CVD mortality with anthropometric measures of abdominal obesity was stronger 
than that with BMI, which may imply a more important role of fat distribution than 
fat accumulation and suggest that an effective obesity prevention strategy should 
emphasize the importance of abdominal obesity. Men had higher CVD mortality 
than women across all categories of anthropometric measures of obesity, which 
further supports the view of higher intra-abdominal fat accumulation in men than in 
women, even in non-obese individuals. Obesity seems slightly to diminish the 
female advantage in CVD mortality, irrespective of diabetes status. This may 
indicate that women may gradually lose their cardiovascular advantage when they 
are obese, probably due to a more pronounced clustering of CVD risk factors 
among obese women.   
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TIIVISTELMÄ 
Tutkimuksen tausta ja tavoitteet: Lihavuudesta on tullut kuudenneksi tärkein 
riskitekijä, joka lisää useiden eri sairauksien aiheuttamaa tautitaakkaa 
maailmanlaajuisesti. Lihavuuden antropometristen mittareiden yhteyttä 
kuolleisuuteen ja eri syöpätyyppien ilmaantuvuuteen on tutkittu useissa 
tutkimuksissa, mutta tämä yhteys on edelleen kiistanalainen. Tämän tutkimuksen 
tavoitteena oli 1) arvioida lihavuuden antropometristen mittareiden epidemiologista 
yhteyttä kuolleisuuteen ja määrittää siihen mahdollinen raja-arvo; 2) tutkia kehon 
painoindeksin (BMI) epidemiologista yhteyttä eri syöpätyyppien ilmaantuvuuteen 
ja määrittää siihen mahdollinen raja-arvo; 3) verrata lihavuuden eri antropometrisiä 
indikaattoreita suhteessa sydän- ja verisuonitautikuolleisuuteen; 4) arvioida sydän- 
ja verisuonitautikuolleisuuden riskiä suhteessa lihavuuteen ja sukupuoleen 
väestössä, ja myös erityisesti diabeetikoilla ja ei-diabeetikoilla. 
Aineisto ja menetelmät: Tutkimus perustuu DECODE (Diabetes Epidemiology: 
Collaborative analysis Of Diagnostic criteria in Europe) ja FINRISKI –
tutkimuksissa kerättyyn aineistoon sisältäen 72 947 eurooppalaista miestä ja 62 798 
naista (I), 26 636 suomalaista miestä ja 28 089 naista (II), 24 686 eurooppalaista 
miestä ja 21 965 naista (III/IV), ja 23 629 eurooppalaista miestä ja 21 965 naista 
(V) iältään 24 vuotta tai enemmän lähtötilanteessa. Painoindeksin (BMI), 
vyötärönympäryksen (WC), vyötärönympärys-lantio –suhteen (WHR), 
vyötärönympärys-pituus –suhteen (WHtR) tai vyötärönympärys - koko –suhteen 
(waist-to-stature ratio) (WSR), vartalotyyppi-indeksin (a body shape index ABSI) 
ja vyötärönympärys-lantio-pituus –suhteen (WHHR) vaarasuhteita (Hazard ratios, 
HRs) laskettiin käyttäen Coxin vaarasuhdemallia vakioimalla useilla mahdollisilla 
sekoittavilla tekijöillä  lähtötilanteessa. Mahdollisen kurvilineaarisen yhteyden 
selvittämiseksi, lihavuuden eri antropometristen mittareiden ei-parametrisiä 
tasoittavia funktioita mallinnettiin yhdessä terveyttä kuvaavien mittareiden kanssa 
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käyttäen spliniregressiomallia. Raja-arvo määritettiin piecewise regressiomallilla 
(II/III). Vaarasuhdetta jokaista eri lihavuusmuuttujien yhden keskihajontayksikön 
nousua kohti suhteessa sydän- ja verisuonitautikuolleisuuteen verrattiin parittaisella 
homogeenisyystestillä (IV). 
Tulokset: BMI:llä, WC:llä and WHtR:llä oli U- tai J-muotoinen yhteys 
kokonaiskuolleisuuteen (I/III). WHR:llä, ABSI:lla ja WHHR:llä havaittiin 
puolestaan lineaarisesti suora yhteys kokonaiskuolleisuuteen. BMI:llä oli J-
muotoinen yhteys sydän- ja verisuonitautikuolleisuuteen (I/II), kun taas 
keskivartalolihavuuden mittareilla (WC, WHR, WHtR tai WSR ja ABSI) oli 
lineaarinen suora yhteys (III). BMI:llä oli U-muotoinen yhteys sekä miesten että 
naisten syöpäkuolleisuuteen, mutta sitä ei ollut havaittavissa tupakoimattomilla (I). 
BMI:llä oli lineaarinen suora yhteys eri syöpätyyppien (paksusuoli-, maksa-, 
munuais- ja virtsarakkosyöpä) ilmaantuvuuteen miehillä, sekä vatsa-, paksusuoli-, 
sappirakko- ja munasarjasyöpään naisilla. Käänteinen yhteys tuli esille miesten 
keuhkosyöpään ja naisten keuhko- ja rintasyöpiin. Naisten kaikkien syöpätyyppien 
ilmaantuvuudella oli J-muotoinen yhteys painoindeksiin (BMI). 
Jokaisen lihavuusindikaattorin yhden keskihajontayksikön nousulla oli merkitsevä 
yhteys, yli 19 prosentin kasvu, sekä miesten että naisten sydän- ja 
verisuonitautikuolleisuusriskiin. Keskivartalolihavuutta kuvaavat antropometriset 
mittarit ennustivat vahvemmin sydän- ja verisuonitautikuolleisuutta kuin kehon 
painoindeksi tai ABSI. Vahvin ennustevoima oli WHtR/WSR:llä (IV). Miehillä oli 
suurempi sydän- ja verisuonitautikuolleisuus ja korkeampi HR kaikissa kehon 
painoindeksi - ja keskivartalolihavuuskategorioissa kuin naisilla (V); sukupuolten 
välillä erot olivat hieman pienemmät lihavilla kuin normaalipainoisilla. 
Negatiivinen yhdysvaikutus oli tilastollisesti merkitsevä sukupuolen ja 
vyötärönympäryksen välillä (p=0.02) ja sukupuolen ja vyötärönympärys-pituus –
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suhteen (WHtR) (p=0.01) välillä. Mikään yhdysvaikutusmuuttuja ei ollut 
merkitsevä tutkittaessa sitä erikseen ei-diabeetikoilla ja diabeetikoilla. 
Päätelmät: Tutkimus vahvistaa lihavuuden haitallisen yhteyden useisiin 
kuolinsyihin ja eräiden syöpätyyppien ilmaantuvuuteen. Keskivartalolihavuuden 
antropometriset mittarit ennustavat vahvemmin sydän- ja 
verisuonitautikuolleisuutta kuin painoindeksi. Tämä saattaa johtua siitä, että rasvan 
jakautumisella kehossa on tärkeämpi merkitys kuin rasvan kasaantumisella sinänsä, 
minkä vuoksi lihavuuden ehkäisyssä tulisi kiinnittää erityisesti huomiota 
keskivartalolihavuuteen. Miesten sydän- ja verisuonitautikuolleisuus on suurempi 
kaikissa lihavuuden antropometrisissä mittauskategorioissa, mikä puolestaan 
vahvistaa käsityksen siitä, että miehillä, jopa normaalipainoisilla, esiintyy 
useammin sisäelinten ympärille ja vatsaonteloon kertynyttä rasvaa kuin naisilla. 
Näyttää siltä, että lihavuus vaikuttaa jonkin verran myös naisten sydän- ja 
verisuonitautikuolleisuuteen sekä diabeetikoilla että ei-diabeetikoilla. Naiset 
saattavat lihoessaan vähitellen menettää etuaan suhteessa sydän- ja 
verisuonitauteihin miehiin verrattuna, mikä voi johtua voimakkaammasta sydän- ja 
verisuonitautiriskitekijöiden kasaantumisesta lihavilla naisilla.   
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1 INTRODUCTION 
The prevalence of obesity has dramatically increased for decades wordwide. 
Obesity is a major risk factor for development of chronic diseases and metabolic 
abnormalities that have high morbidity and mortality (1,2), and may also have an 
adverse effect on psychosocial health and well-being (3). Most studies have found 
that a high level of anthropometric measures of obesity is associated with an 
increased risk of mortality from various causes among adult Caucasians (2,4-13). 
However, the association of anthropometric measures of obesity with mortality 
from various causes remains controversial: a J-shaped, a U-shaped, a positive or no 
association (2,4-31). Moreover, it has been consistently shown that high Body mass 
index (BMI) is associated with an increased risk of incidence of cancers of the 
colon (32-37), pancreas (11,33,38-41), kidney (11,36,42-44) and ovary (11,45-48), 
but with a decreased risk of incidence of cancer of the lung (11,36,49-51). No 
association is evident for BMI with incidence of cancers of the prostate (52-58) and 
rectum (34,35,59-62). The relationship between BMI and incidence of cancers of 
other sites, however, remains inconsistent: a positive, an inverse or no association 
(11,33,63-76).  
  BMI is the most common measure for contemporary diagnosis of general obesity 
in both clinical practice and epidemiological studies (77). In 1995, the World 
Health Organization (WHO) proposed to define Caucasian individuals as 
underweight (BMI <18.5 kg/m
2
), normal weight (BMI 18.5-24.9 kg/m
2
), 
overweight (BMI 25.0-29.9 kg/m
2
) and obese (BMI ≥30.0 kg/m2) (78). Waist 
circumference (WC), waist-to-hip ratio (WHR) and waist-to-height ratio (WHtR) 
or waist-to-stature ratio (WSR) are used as surrogate anthropometric measures of 
abdominal obesity (79-81). Currently, the most often used definitions for central 
obesity among adult Caucasians are WC of 102 cm and 88 cm (82), or of 94 cm 
and 80 cm (83), or WHR of 0.95 and 0.80 (82) in men and in women, respectively. 
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These existing cut-off values have, however, been determined arbitrarily based on 
analysis of the trade-offs between sensitivity and specificity for discrimination of 
diabetes or metabolic syndrome (84). Most of these previous studies were cross-
sectional (82). Less is known about whether thresholds for anthropometric 
measures of obesity exist in predicting cardiovascular disease (CVD) mortality 
risk.  
  BMI does not distinguish between muscle and fat accumulation, or between fat 
locations, hence it is recognized as a crude surrogate for general obesity. WC or 
WHtR appears to be a better indicator of abdominal obesity than BMI inasmuch as 
the correlation of cardiometabolic risk factors with intra-abdominal fat content is 
higher than the corresponding correlation with BMI (85-92). Several studies have 
reported that relative risks for CVD mortality corresponding to a one-standard-
deviation increment in anthropometric measures of abdominal obesity are higher 
than that of BMI (14,19,93-95), but none of these studies have performed a formal 
statistical test.  
  Further, middle-aged women are known to have a much lower CVD mortality 
than men. Epidemiological studies have shown that men tend to have a higher 
prevalence of abnormal levels of conventional CVD risk factors than women, such 
as hypertension, smoking, lipid abnormalities and obesity (96,97). However, this 
female advantage is abrogated with diabetes and aging (96,98-105). The prevalence 
of obesity is rising worldwide, leading to increased risks of diabetes and CVD 
(106,107). It is unclear, however, whether the sex difference in CVD mortality 
remains with the development of obesity.  
  The purpose of this study was to examine the association of anthropometric 
measurements of obesity with mortality and cancer incidence among European 
adults, to explore a better anthropometric measure of obesity in relation to CVD 
mortality and sex differences in these associations. The results give evidence on 
detrimental effect of obesity on mortality and cancer incidence and a better 
18 
 
anthropometric measure of obesity in relation to CVD mortality with threshold 
values detected, which could be used to direct a more effective obesity prevention 
strategy.   
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2 REVIEW OF THE LITERATURE 
2.1 Obesity 
Definition of obesity based on anthropometric measures 
Obesity is associated with both increased fat cell size and number within adipose 
tissue (108,109). Even though the gold-standard definition of obesity by the WHO 
is an excess in body fatness (>25% in men and >35% in women) (77), BMI is 
the most common measure for contemporary diagnosis of general obesity in both 
clinical practice and epidemiological studies (77). In 1995, the WHO proposed to 
define Caucasian individuals as underweight (BMI <18.5 kg/m
2
), normal weight 
(BMI 18.5-24.9 kg/m
2
), overweight (BMI 25.0-29.9 kg/m
2
) and obese (BMI ≥30.0 
kg/m
2
) (78). WC, WHR and WHtR/WSR are used as surrogate anthropometric 
measures of abdominal obesity (79-81). Currently, the most often used definitions 
for central obesity among Caucasians are WC of 102 cm and 88 cm (82), or of 94 
cm and 80 cm (83), or WHR of 0.95 and 0.80 (82) in men and in women, 
respectively.  
Causes of obesity 
The causes of obesity are multifactorial: environmental, behavioral, and genetic 
factors can all contribute to its development. There is a common agreement among 
experts that the environment, rather than biology, is driving the obesity epidemic 
through discouraging expenditure of energy, leading to an imbalance between the 
energy ingested in food and the energy expended (110), although the relative 
contributions of factors to obesity are not properly known. It is challenging and of 
considerable interest to identify the biological initiating and driving forces for this 
energy imbalance, by increased food intake and/or decreased energy expenditure, 
as well as disturbed fat accumulation in adipose tissue (111). Low socioeconomic 
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status and genetic variations might play a role in the development of obesity as 
well (112-117).  
2.2 Anthropometric measures of obesity and health 
outcomes 
2.2.1 Anthropometric measures of obesity and all-cause mortality 
BMI and all-cause mortality  
Most studies have found that BMI has a J- (4,21,118-120) or U-shaped 
(2,5,6,16,19,22-26,121-123) association with all-cause mortality adjusting for a 
variety of confounding variables. Katzmarzyk et al found that BMI had a positive 
relationship with all-cause mortality in Canadian women adjusting for age, 
smoking status and alcohol consumption (15). Lahmann et al also found that BMI 
had a non-significant positive association with all-cause mortality in Swedish 
women adjusting for age, smoking status and alcohol consumption, perhaps due to 
a limited duration of follow-up (27).  
WC and all-cause mortality 
Several studies have found that WC has a U- or J-shaped (2,12,15-19), or a linear 
positive (8,13-16) association with all-cause mortality. Cameron et al found a non-
significant association between WC and all-cause mortality adjusting for age, 
smoking status and self-reported history of CVD or cancer (31).  
WHR and all-cause mortality 
Most studies have found that WHR has a linear positive association with all-cause 
mortality (2,8,13,14,16,27,124). Hotchkiss et al found a U-shaped association 
between WHR and all-cause mortality in Scottish women adjusting for age, 
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smoking status, alcohol consumption and year of survey (18). Simpson et al found 
a U-shaped relationship between WHR and all-cause mortality in Australian 
women adjusting for age, country of birth, physical activity, alcohol intake, 
education, and smoking status (16). Cameron et al found a non-significant 
association between WHR and all-cause mortality adjusting for age, smoking status 
and self-reported history of CVD or cancer (31).  
WHtR and all-cause mortality 
Two studies have found that WHtR has a linear positive relationship with all-cause 
mortality (94,125), whereas Petursson et al found a linear positive relationship in 
Norwegian men in contrast to a J-shaped relation in women (14).  
A body shape index (ABSI) and all-cause mortality 
A new measure, ABSI has been proposed to have a linear positive association with 
all-cause mortality (19).  
2.2.2 Anthropometric measures of obesity and CVD mortality  
Several studies have found that BMI has a linear positive (6,7,21-23,25,26,28), a J- 
or U-shaped (5,8,14,28,29,126,127) association with CVD mortality, whereas most 
anthropometric measures of abdominal obesity show a linear positive relationship 
with CVD mortality (2,8,12-14,128).  
2.2.3 BMI and incidence of cancer 
Most studies have found that BMI has a positive association with incidence of 
colon cancer (32-37), pancreatic cancer (11,33,38-41), ovarian cancer (11,45-48), 
kidney cancer (11,36,42-44) and breast cancer among postmenopausal women 
(11,33,63,66-70,129), and an inverse association with incidence of lung cancer 
(11,36,49-51) or with breast cancer among premenopausal women 
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(63,66,69,70,129,130), but no association with incidence of rectal cancer 
(34,35,59-62) or prostate cancer (52-58). The relationship between BMI and 
incidence of cancer of other sites is still inconsistent: an inverse relationship (36) or 
no association (11,72) with stomach cancer, a non-significant positive association 
with liver cancer (33,36,73,74), a linear positive (71,131) relationship or no 
association (36) with gallbladder cancer, a linear relationship (11,73) or no 
association (33) with cervical cancer, a linear positive relationship (75) or no 
association (11,33,36,76) with bladder cancer, and a non-significant positive 
association with all cancers combined (11,33,36).  
2.2.4 BMI and cancer mortality  
The relationship between BMI and cancer mortality is still inconsistent: a positive 
(4,9,10,20), a U- or J-shaped (11,25) relationship or no association 
(7,21,22,24,29,30).  
2.3 Comparison of strengths of different anthropometric 
measures of obesity in relation to CVD mortality  
BMI does not distinguish between muscle and fat accumulation, or between fat 
locations, hence it is recognized as a crude surrogate for general obesity. WC or 
WHtR appears to be a better indicator of abdominal obesity than BMI inasmuch as 
the correlation of cardiometabolic risk factors with intra-abdominal fat content is 
higher than the corresponding correlation with BMI (85-92). Several studies have 
reported that relative risks for CVD mortality corresponding to a one-standard-
deviation increment in anthropometric measures of abdominal obesity are higher 
than that of BMI (14,19,93-95), but none of these studies have performed a formal 
statistical test.   
23 
 
2.4 Sex differences in CVD risk 
Female cardiovascular advantage 
Middle-aged women are known to have a much lower CVD mortality than men. 
Epidemiological studies have shown that men tend to have a higher prevalence of 
abnormal levels of conventional CVD risk factors than women, such as 
hypertension, smoking, lipid abnormalities and obesity (96,97). There is substantial 
evidence of a sex difference in cardiac autonomic modulation (132-135), lipid and 
glucose metabolism (136-139), sex hormones (134,140-144) and cytokines (145-
149). On average, women have augmented sympathetic inhibition, higher cardiac 
vagal tone, higher heart rate variability, lower susceptibility to arrhythmias, and 
decreased myocardial contractility than men (132,133,150), leading to a 
preponderance of vagal over sympathetic control of cardiac function (132-135).  
Influence of menopause status on cardiovascular risk factors 
Before menopause, middle-aged women generally have lower levels of serum 
total and low-density lipoprotein cholesterol (Total-C and LDL-C), triglycerides 
(TG) and apolipoprotein B and higher levels of high-density lipoprotein 
cholesterol (HDL-C) and apolipoprotein A-I than their male counterparts 
(136,151-153), although Total-C and LDL-C increase in women after menopause 
(151,152).  
Influence of diabetes on sex differences of cardiovascular mortality 
Female cardiovascular advantage is abrogated with diabetes and aging (96,98-105), 
perhaps as a consequence of diabetes inducing higher levels of inflammatory 
markers and impairment of higher rates of nitric oxide release in women compared 
with men, resulting in reduced protective effects of estrogen on body fat 
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distribution and insulin action, or a more impaired endothelial function in women 
than in men (140,154).  
2.5 Confounding factors in study of obesity and health 
outcomes  
Age 
Fat tissue mass increases through middle age and declines in old age (155,156). Fat 
is redistributed among different fat depots over time, especially during and after 
middle age from subcutaneous to intra-abdominal visceral depots (156-161). 
Visceral adipose tissue (VAT) accumulation increases more rapidly in women with 
aging, especially after menopause (141,162), despite the higher VAT accumulation 
in men than in women throughout the life span (162,163).  
Smoking status  
Even though smoking is known to decrease body weight, it is associated with an 
increase in abdominal obesity (164-168), perhaps through simultaneously affecting 
lipoprotein lipase activity and increasing cortisol levels (167,168). One study found 
a reduced visceral fat accumulation in Turkish female smokers (169). Smoking has 
been well known to be associated with increased risks of CVD (170), type 2 
diabetes (171-175) and mortality (16,176-178).  
Leisure-time physical activity  
A sedentary lifestyle is an independent risk factor for all-cause and CVD mortality, 
and also contributes to obesity (179,180). Physical activity has been reported to 
attenuate or eliminate the relation between BMI and the risk of incidence of 
cancers of the colon, rectum and pancreas (35,38), perhaps through improving 
insulin resistance and increasing adiponectin levels (181-185). Limited evidence 
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indicates that leisure-time physical inactivity might play an intermediate role 
between the relationship of anthropometric measures of abdominal obesity and 
mortality (186), and weaken, but not eliminate, the risk associated with excess 
weight (176).  
Reverse causality 
‘Reverse causality’, which refers to illness-associated weight loss and higher 
mortality (106,187), may bias observed associations between anthropometric 
measures of obesity and mortality or incidence.   
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2.6 A summary of the literature 
This literature review focused on epidemiological studies on the association 
between anthropometric measures of obesity and mortality from various causes and 
cancer incidence, and sex differences in prevalence of abnormal levels of 
conventional CVD risk factors.  
  Evidence of the association between a high level of anthropometric measures of 
obesity and an increased risk of mortality from various causes among adult 
Caucasians is very strong, however, the association of anthropometric measures of 
obesity with mortality from various causes remains controversial, and there is very 
little evidence of a threshold detected. Several studies have reported that relative 
risks for CVD mortality corresponding to a one-standard-deviation increment in 
anthropometric measures of abdominal obesity are higher than that of BMI, but 
none of these studies have performed a formal statistical test. Studies concerning 
the association between BMI and incidence of cancers of various sites are scarce 
and the evidence is less convincing, especially for some rare types of cancer. 
Inconsistent findings could be partially attributed to confounding factors, reverse 
causality or methodological issues, for instance, statistical models or time-scale 
used that may bias associations.  
  The prevalence of obesity is rising worldwide, leading to increased risks of 
diabetes and CVD. Despite the fact that middle-aged women are known to have a 
much lower CVD mortality than men, this female advantage is abrogated with 
diabetes and aging. Several epidemiological studies have shown that middle-aged 
men tend to have a higher prevalence of abnormal levels of conventional CVD risk 
factors than women, such as hypertension, smoking, lipid abnormalities and 
obesity. It is unclear whether the sex difference in CVD mortality remains with the 
development of obesity.   
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3 AIMS OF THE STUDY 
The general aims of this thesis were to examine the association of anthropometric 
measurements of obesity with mortality and cancer incidence among European 
adults, to identify the potential threshold, to explore a better anthropometric 
measure of obesity in relation to CVD mortality and sex differences in these 
associations.  
The specific aims of the study were: 
1) To evaluate the epidemiological nature of the association of anthropometric 
measures of obesity with mortality from various causes, and to detect a potential 
threshold (Studies I and III)  
2) To study the epidemiological nature of body mass index and incidence of cancer 
of different sites, and to detect a potential threshold (Study II)  
3) To compare the strengths of various anthropometric measures of obesity in 
relation to CVD mortality (Study IV)  
4) To assess the risk of CVD mortality in relation to obesity and sex in the general 
population, and separately for those with or without diabetes at baseline (Study V)   
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4 STUDY POPULATION AND METHODS  
4.1 Study population 
The Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in 
Europe (the DECODE) study is one of the largest epidemiological studies on 
hyperglycemia and other metabolic disorders in the world, comprising almost 40 
mainly population- or occupation-based cohorts from 14 countries in Europe, with 
about 84 000 Europeans included in the collaboration (188). All survey participants 
included in the data analysis are Caucasians (Appendix). The study populations 
varied according to inclusion/exclusion criteria (Table 1), and comprised 135 745 
Europeans (72 947 men and 62 798 women) from 33 individual studies (Study I), 
46 651 Europeans (24 686 men and 21 965 women) from 12 individual studies 
(Studies III/IV), and 45 594 Europeans (23 629 men and 21 965 women) from 11 
individual studies (Study V), respectively.  
  Population-based surveys on CVD and other non-communicable disease risk 
factors have been conducted in selected areas of Finland every 5 years since 1972 
(189). Seven FINRISK cohort studies of 1972, 1977, 1982, 1987, 1992, 1997 and 
2002 were included in the current data analysis (Table 1). All seven surveys 
included people who were 24-64 years of age, and the 1997 and 2002 surveys also 
included people aged 65-74 years. A total of 54 725 Finns (21 148 men and 18 437 
women) were included in the data analysis (Study II).  
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Table 1 Inclusion/Exclusion criteria of the study populations 
Study Data 
source 
Inclusion criteria Exclusion criteria 
I DECODE 1) Population- or occupation-based cohort study with 
data on cause-specific mortality;  
2) Participants aged 24–99 at baseline;  
3) The availability of sex, baseline body weight, height 
and smoking status.  
1) Individuals without exact 
date of emigration or 
completely lost to follow-up.  
II FINRISK 1) Population-based cohort study with valid data on 
diagnosis of incident cancer of various sites and dates; 
2) Participants aged 24-74 years; 
3) The availability of sex, baseline body weight, height, 
smoking status, leisure-time physical activity and 
schooling years.  
1) Individuals completely lost 
to follow-up;  
2) Individuals with cancer at 
enrolment.  
III-V DECODE 1) Population- or occupation-based cohort study with 
data on CVD mortality;  
2) Participants aged 24-99 at baseline; 
3) The availability of sex, baseline body weight, height, 
waist circumference and hip circumference, smoking 
status and leisure-time physical activity.  
1) Individuals without exact 
date of emigration or 
completely lost to follow-up. 
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4.2 Measurements 
Anthropometric measures of obesity 
Height and weight were measured without shoes and with light clothing. WC was 
measured midway between the lower rib margin and iliac crest. Hip circumference 
was measured at the level of the widest circumference over the greater trochanters. 
BMI was calculated as weight in kilograms divided by the square of height in 
meters. WHR, WHtR/WSR, or WHHR was calculated as WC divided by hip 
circumference, height, or both in meters, respectively. The calculation of ABSI was 
based on WC adjusted for weight and height, which was defined as follows: 
ABSI=WC height
5/6
 weight
-2/3
 (19). General obesity was defined as a BMI level of 
≥30.0 kg/m2 in both sexes, whereas abdominal obesity based on the sex-specific 
top quartile of WC, WHR or WHtR (WC ≥99 cm, WHR ≥0.97, and WHtR ≥0.57 
for men; WC ≥90 cm, WHR ≥0.85, and WHtR ≥0.56 for women, respectively) for 
comparison purposes (Study V).  
Assessment of smoking status, leisure-time physical activity and education status  
Based on responses to the questionnaire, smoking status at baseline was classified 
into three categories of never, former and current smokers (Studies I-V). Reading, 
watching TV, housework, sewing and walking <1 km daily were defined as 
physically inactive; all those engaging in higher levels of physical activity were 
defined as physically active (Studies II-V). Education was classified into three 
categories (≤9, 10-12, >13 schooling years) (Study II).  
Laboratory measurements and assays 
Diabetes was defined as either a self-reported history of diabetes at baseline or a 
fasting plasma glucose (FPG) level of ≥7.0 mmol/L and/or a 2-hour plasma glucose 
(2hPG) level of ≥11.1 mmol/L (79) (Study V).   
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4.3 Definition of end-points 
CVD mortality was defined according to the International Classification of Disease 
(ICD) codes 331, 420 (7th revision), 401–448 (8th or 9th revision) and codes I10–
I79 (10th revision) (Studies I, III-V). Cancer mortality was defined as cancers of all 
types by the ICD codes 158, 162, 181, 193, 199, 200, 204 (7th revision), 140–239 
(8th or 9th revision) and codes C00–C97, D00–D09 (10th revision) (Study I).  
  Information on incidence of cancers was obtained from the Finnish Cancer 
Registry (FCR) and the dates of death from the cause-of-death register of Statistics 
Finland by computer-based record linkage using the unique personal identity codes 
assigned to every resident of Finland (Study II). The data coverage in the FCR is 
virtually complete, 99% for solid tumours, and the data accuracy is high as 
previously validated by different researchers (190).  
  The FCR uses International Classification of Diseases for Oncology, 3rd (ICD-O-
3) in classification of the cancer cases. For the current study, cancers were 
categorised into following sites: any site (C000-C809), stomach (C16), colon (C18-
C19), rectum (C20), liver (C220), gallbladder and extrahepatic bile ducts (C23-
C24), pancreas (C25), lung (C34), breast (C50), cervix uteri (C53), ovary (C56), 
prostate (C61), kidney (C649) and bladder (C67). Only the first occurrence of 
cancer after the baseline examination was included in the analysis, subsequent 
cancers of the same site or not were excluded and people with a cancer diagnosed 
before the baseline survey were excluded from the cohort (n =1173, 1.9%). Follow-
up of each cohort member started from the date of baseline survey and continued 
until the date of first cancer diagnosis, date of death, or 31 December, 2008, 
whichever was the earliest.  
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4.4 Ethical considerations 
Individual participant data from each cohort was sent to the National Institute for 
Health and Welfare in Helsinki, Finland for collaborative data analyses. Each study 
was approved by the local ethics committees, and the analysis plan was approved 
by the ethics committee of the National Institute for Health and Welfare, Helsinki, 
Finland.  
4.5 Statistical analyses 
Hazard ratios (HR) and their 95% confidence intervals (CI) were estimated by the 
Cox proportional hazards model using follow-up time (Study I) or age (Studies II-
V) as the time-scale, adjusting for baseline risk factors. The proportional hazards 
assumptions were tested and met for all studies. Because the death from CVD and 
cancers are mutually exclusive, the probability of the CVD mortality was estimated 
in the presence of competing risk of cancer mortality or vice versa (Study I), in 
order to evaluate a possible overestimate of the cumulative mortality (191). 
Interactions between anthropometric measure of obesity and factors were checked 
in the Cox models, using a chi-squared log-likelihood ratio test. Non-parametric 
smooth functions of anthropometric measures of obesity in relation to mortality 
were fitted to explore the curvilinear relationship using a linear or restricted cubic 
spline regression model, with threshold detected by a piecewise regression model 
(Studies II/III). Akaike’s information criterion (AIC) was used to judge the model 
fitness between their conventional linear model and polynomial models (including 
quadratic, cubic or fractional polynomial model), the lower the AIC value the better 
the model fitness, with reduction of AIC evaluated by the likelihood ratio test 
(LRT) or a deviance difference test (192,193) (Studies II-IV). AIC difference ≥4 
was considered to be considerably less supported relative to the lowest AIC value 
between non-nested models (194) (Study III). HR per standard deviation increase 
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of each anthropometric measure of obesity in relation to CVD mortality was 
formally compared by paired homogeneity test, which is a Wald test of the linear 
hypothesis of the Cox model regression coefficients, performed to test the null 
hypothesis of equality of the effect sizes (Study IV).   
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5 RESULTS 
5.1 Natural relationship between anthropometric 
measures of obesity and all-cause mortality (Studies I and 
III) 
Baseline characteristics of the cohorts and the follow-up data are shown in Table 1 
in Study I and Table 2. Over a median follow-up of 16.8 years, 29 071 participants 
died, 13 502 (46%) from CVD and 8 748 (30%) from cancers of all types (see 
Table 1 in Study I). Over a median follow-up of 7.9 years, 2381 men and 1055 
women died, 1071 men (45%) and 339 women (32%) from CVD (Table 2). Table 
3 shows that old age, high distribution of anthropometric measures of obesity, 
smoking and leisure-time physical inactivity were significantly associated with all-
cause mortality.  
Relationship between categorical BMI and all-cause mortality (Study I) 
Crude mortality rates per 1000 person-years and HRs (95% CI) for mortality from 
various causes corresponding to a one-unit increase in BMI adjusted for age, cohort 
and smoking status are shown in Figure 1 and online Tables 1-2 in Study I. All-
cause mortality decreased first, leveled off, and then increased with increasing BMI 
levels (kg/m
2
), which indicates a U-shaped relationship with the lowest all-cause 
mortality in the BMI interval of 23.0 to 28.0 kg/m
2
 in men and 21.0 to 28.0 kg/m
2
 
in women approximately. Further, the U-shaped relationship did not change 
substantially after exclusion of deaths occurring during the first five-year follow-
up. The smoking-BMI interaction was significant for all-cause mortality in both 
men and women and the U-shaped relationship held after a data analysis stratified 
by smoking status (see Table 3 in Study I). For most studies, study-specific HRs 
were within 10% of the pooled estimate, although there was evidence of  
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Table 2 Baseline characteristics and the follow-up data of the survey (Studies III-V) 
Study 
No. of 
participants 
Age 
(years) 
BMI 
(kg/m
2
) 
WC 
(cm) 
WHtR WHR 
ABSI (m
11/6
 
kg
-2/3
) 
WHHR 
(m
-1
) 
Median  
follow-up 
(years) 
No. of deaths 
CVD 
(%) 
All-
cause 
Men            
Finland            
 FINRISK (1987) 2541 
43.8 
(11.2) 
26.7 (3.7) 
92.2 
(10.7) 
0.53 
(0.06) 
0.90 
(0.06) 
0.0784 
(0.0041) 
0.52 
(0.04) 
21.8 
293 
(52) 
561 
 FINRISK (1992) 2570 
44.3 
(11.2) 
26.6 (3.9) 
93.9 
(11.2) 
0.53 
(0.07) 
0.92 
(0.07) 
0.0796 
(0.0040) 
0.52 
(0.05) 
16.8 
152 
(45) 
340 
 FINRISK (1997) 3788 
48.6 
(13.5) 
26.9 (3.9) 
94.5 
(11.3) 
0.54 
(0.07) 
0.93 
(0.07) 
0.0796 
(0.0040) 
0.53 
(0.05) 
11.8 
205 
(49) 
418 
 FINRISK (2002) 3808 
48.0 
(13.0) 
27.2 (4.1) 
95.4 
(11.8) 
0.54 
(0.07) 
0.97 
(0.07) 
0.0796 
(0.0041) 
0.55 
(0.05) 
6.8 
69 
(43) 
162 
Sweden            
 Uppsala (1991-
1995)* 
1057 
71.0 
(0.6) 
26.2 (3.4) 
94.4 
(9.4) 
0.54 
(0.05) 
0.94 
(0.05) 
0.0811 
(0.0037) 
0.54 
(0.04) 
10.0 
126 
(46) 
276 
 Northern Sweden 
MONICA (1986) 
671 
46.0 
(11.4) 
25.4 (3.4) 
92.4 
(9.2) 
0.52 
(0.06) 
0.94 
(0.05) 
0.0806 
(0.0032) 
0.54 
(0.04) 
20.5 
49 
(37) 
131 
 Northern Sweden 
MONICA (1990) 
761 
45.0 
(11.3) 
25.8 (3.4) 
91.4 
(9.1) 
0.52 
(0.05) 
0.93 
(0.06) 
0.0789 
(0.0036) 
0.53 
(0.04) 
16.5 
30 
(38) 
79 
 Northern Sweden 
MONICA (1994) 
877 
49.6 
(14.0) 
26.2 (3.7) 
93.4 
(10.1) 
0.53 
(0.06) 
0.94 
(0.06) 
0.0799 
(0.0040) 
0.53 
(0.04) 
12.5 
37 
(29) 
126 
 Northern Sweden 
MONICA (1999) 
869 
50.6 
(14.3) 
26.7 (3.5) 
95.3 
(9.7) 
0.54 
(0.06) 
0.92 
(0.07) 
0.0805 
(0.0039) 
0.52 
(0.05) 
7.4 
14 
(25) 
56 
 Northern Sweden 
MONICA (2004) 
864 
50.9 
(14.1) 
27.2 (4.0) 
96.4 
(10.7) 
0.54 
(0.06) 
0.96 
(0.06) 
0.0803 
(0.0036) 
0.54 
(0.04) 
2.5 0 (0) 7 
Turkey            
 TARFS (1998-
2002) 
1580 
53.2 
(12.4) 
26.4 (4.0) 
94.3 
(11.0) 
0.56 
(0.06) 
0.93 
(0.07) 
0.0819 
(0.0052) 
0.55 
(0.05) 
7.9 
55 
(50) 
109 
UK            
 Whitehall II (1991-
1993) 
5300 
49.3 
(6.0) 
25.1 (3.2) 
87.4 
(9.2) 
0.50 
(0.05) 
0.90 
(0.06) 
0.0768 
(0.0035) 
0.51 
(0.04) 
5.9 
41 
(35) 
116 
Total 24 686 
49.0 
(12.4) 
26.3 (3.8) 
92.7 
(11.0) 
0.53 
(0.06) 
0.93 
(0.07) 
0.0792 
(0.0042) 
0.53 
(0.05) 
7.9 
1071 
(45) 
2381 
Women            
Finland            
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 FINRISK (1987) 2812 
43.7 
(11.4) 
26.0 (4.9) 
79.4 
(11.2) 
0.49 
(0.07) 
0.78 
(0.06) 
0.0714 
(0.0045) 
0.48 
(0.05) 
21.8 
119 
(38) 
310 
 FINRISK (1992) 2828 
44.0 
(11.5) 
25.7 (4.9) 
80.2 
(11.7) 
0.49 
(0.08) 
0.79 
(0.07) 
0.0724 
(0.0043) 
0.49 
(0.05) 
16.9 
55 
(29) 
190 
 FINRISK (1997) 3788 
46.1 
(12.7) 
26.1 (5.0) 
81.3 
(12.2) 
0.50 
(0.08) 
0.80 
(0.07) 
0.0726 
(0.0042) 
0.49 
(0.05) 
11.8 
61 
(35) 
176 
 FINRISK (2002) 4383 
46.6 
(13.0) 
26.4 (5.1) 
83.6 
(12.6) 
0.52 
(0.08) 
0.84 
(0.06) 
0.0742 
(0.0042) 
0.52 
(0.05) 
6.8 
14 
(24) 
58 
Sweden            
 Northern Sweden 
MONICA (1986) 
685 
45.6 
(11.1) 
25.0 (4.4) 
85.3 
(12.2) 
0.52 
(0.08) 
0.86 
(0.07) 
0.0783 
(0.0054) 
0.53 
(0.05) 
20.5 
18 
(24) 
75 
 Northern Sweden 
MONICA (1990) 
793 
44.8 
(11.4) 
25.0 (4.4) 
79.4 
(11.0) 
0.49 
(0.07) 
0.81 
(0.06) 
0.0729 
(0.0042) 
0.50 
(0.04) 
16.5 
12 
(24) 
51 
 Northern Sweden 
MONICA (1994) 
902 
49.4 
(14.0) 
25.8 (4.7) 
84.2 
(12.4) 
0.52 
(0.08) 
0.83 
(0.08) 
0.0757 
(0.0060) 
0.51 
(0.06) 
12.5 
16 
(24) 
68 
 Northern Sweden 
MONICA (1999) 
900 
50.1 
(14.1) 
26.4 (4.6) 
84.9 
(11.8) 
0.52 
(0.08) 
0.82 
(0.07) 
0.0753 
(0.0047) 
0.50 
(0.05) 
7.5 3 (11) 27 
 Northern Sweden 
MONICA (2004) 
909 
49.7 
(13.9) 
26.6 (5.1) 
86.6 
(12.9) 
0.53 
(0.08) 
0.85 
(0.07) 
0.0761 
(0.0045) 
0.52 
(0.05) 
2.5 0 (0) 5 
Turkey            
 TARFS (1998-
2002) 
1619 
52.7 
(12.3) 
28.8 (5.7) 
90.7 
(12.7) 
0.58 
(0.09) 
0.84 
(0.08) 
0.0778 
(0.0072) 
0.54 
(0.06) 
7.9 
35 
(63) 
56 
UK            
 Whitehall II (1991-
1993) 
2346 
50.2 
(6.1) 
25.7 (4.7) 
75.5 
(11.7) 
0.47 
(0.07) 
0.77 
(0.07) 
0.0683 
(0.0052) 
0.48 
(0.05) 
5.8 6 (15) 39 
Total 21 965 
46.9 
(12.3) 
26.2 (5.0) 
82.0 
(12.6) 
0.51 
(0.08) 
0.81 
(0.07) 
0.0733 
(0.0054) 
0.50 
(0.05) 
11.8 
339 
(32) 
1055 
Abbreviations: BMI, body mass index; WC, waist circumference; WHtR, waist-to-height ratio; WHR, waist-to-hip ratio; ABSI, A Body Shape Index; WHHR, 
waist-to-hip-to-height ratio; CVD, cardiovascular disease.  
Data are means (standard deviations) or as noted.  
*Uppsala (1991-1995) not included in Study V.  
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Table 3 Baseline characteristics of participants in studies I and III according to all-cause mortality* 
 
Study I  Study III 
All-cause deaths All-cause deaths 
No Yes No Yes 
Men      
Number  53 777 19 170  22 305 2381 
Age (years) 47.1 (47.0-47.2) 53.0 (52.8-53.1)†  48.9 (48.7-49.0) 59.8 (59.0-60.7)† 
BMI (kg/m
2
) 25.8 (25.8-25.9) 25.9 (25.9-26.0)†  26.3 (26.3-26.4) 26.7 (26.5-26.8)† 
WC (cm) - -  92.5 (92.4-92.7) 94.4 (94.0-94.9)† 
WHtR - -  0.53 (0.53-0.53) 0.54 (0.54-0.54)† 
WHR - -  0.93 (0.93-0.93) 0.94 (0.93-0.94)† 
ABSI (m
11/6
 kg
-2/3
) - -  0.0790 (0.0790-0.0791) 0.0803 (0.0801-0.0804)† 
WHHR (m
-1
) - -  0.53 (0.53-0.53) 0.54 (0.54-0.54)† 
Leisure-time physically inactive, % - -  18.3 28.1† 
Smoking status, %      
 Former smokers  24.9 21.9  31.3 30.0 
 Current smokers  33.8 53.3†  23.2 37.3† 
Women      
Number 52 897 9901  20 910 1055 
Age (years) 47.5 (47.4-47.6) 54.5 (54.3-54.7)†  46.9 (46.7-47.1) 59.2 (57.9-60.4)† 
BMI (kg/m
2
) 25.8 (25.7-25.8) 26.6 (26.5-26.7)†  26.2 (26.1-26.2) 26.8 (26.5-27.1)† 
WC (cm) - -  81.9 (81.7-82.0) 84.0 (83.3-84.7)† 
WHtR - -  0.51 (0.51-0.51) 0.52 (0.52-0.53)† 
WHR - -  0.81 (0.81-0.81) 0.82 (0.82-0.82)† 
ABSI (m
11/6
 kg
-2/3
) - -  0.0732 (0.0731-0.0733) 0.0742 (0.0739-0.0746)† 
WHHR (m
-1
) - -  0.50 (0.50-0.50) 0.51 (0.51-0.51)† 
Leisure-time physically inactive, % - -  23.5 36.3† 
Smoking status, %      
 Former smokers 13.4 6.2  18.3 13.6 
 Current smokers 22.3 26.4†  18.8 25.5† 
Abbreviations: BMI, body mass index; WC, waist circumference; WHtR, waist-to-height ratio; WHR, waist-to-hip ratio; ABSI, A Body Shape Index; WHHR, 
waist-to-hip-to-height ratio.  
*Data are age-adjusted means (95% confidence intervals) or as noted.  
†P <0.05 for the difference between no and yes. 
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heterogeneity among studies (I
2
 =73.8%, p =0.000, Figure 1, unpublished results in Study I). 
Exclusion of any study in the analysis had little overall influence on the main results (data not 
shown).  
Model fitness of parametric and nonparametric modeling (Study III) 
The best-fitting conventional model was a conventional polynomial model for BMI, WC and WHtR 
in relation to all-cause mortality in both sexes (p <0.05 for LRT and for deviance difference test 
against a conventional linear model), which suggests a nonlinear relationship (see online Table 1 in 
Study III). However, the best-fitting conventional model was observed as a conventional linear 
model for WHR, ABSI and WHHR in relation to all-cause mortality, of which model fitness was 
not significantly improved by a conventional polynomial model (p ≥0.05 for LRT or for deviance 
difference test against a conventional linear model), which indicates a linear relationship. The 
relationships detected by parametric conventional modeling were further supported by 
nonparametric modeling without considerable difference between the best conventional and spline 
models (AIC difference <4).  
Relationship between anthropometric measures of obesity and all-cause mortality by spline 
regression model (Study III) 
BMI, WC and WHtR had a U- or J-shaped association with all-cause mortality in both sexes, which 
indicates the existence of two potential thresholds (see Figures 2 a-c and g-i in Study III). HR for 
WHR, ABSI and WHHR with all-cause mortality in both sexes increased positively with increasing 
levels (see Figures 2 d-f and j-l in Study III).  
Threshold of anthropometric measures of obesity in relation to all-cause mortality (Study III) 
Threshold values corresponding to a steeper increase in all-cause mortality were detected at 29.88 
and 29.50 kg/m
2
 for BMI, 104.3 and 105.6 cm for WC, 0.61 and 0.67 for WHtR, 0.95 and 0.86 for 
WHR, 0.0807 and 0.0765 m
11/6
 kg
-2/3
 for ABSI in men and women, respectively, and 0.52 m
-1
 for 
WHHR in women (see Figure 3 in Study III).  
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Figure 1 a 
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Figure 1 Forest plot (random-effects model) of individual studies assessing the hazard ratio 
for all-cause mortality corresponding to a one-unit increment of body mass index (BMI) in 
men (a) and women (b, Study I). The width of horizontal line represents 95% confidence intervals 
(CI) of the individual studies, and the grey boxes represents the weight of each study. The diamond 
represents the overall summary estimate. The unbroken vertical line was set at the null value (HR 
=1.0).  
  
Figure 1 b 
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5.2 Natural relationship between anthropometric measures of obesity 
and CVD mortality (Studies I and III)  
Baseline characteristics of the cohorts and the follow-up data are presented in Table 1 in Study I 
and Table 2. Table 4 shows that old age, high distribution of anthropometric measures of obesity 
and leisure-time physical inactivity were significantly associated with CVD mortality. Current 
smoking was associated with CVD mortality in both sexes in Study III but not in women in Study I.  
Relationship between categorical BMI and CVD mortality (Study I) 
Crude mortality rates per 1000 person-years and HRs (95% CI) for CVD mortality corresponding to 
a one-unit increase in BMI adjusted for age, cohort and smoking status are shown in Figure 1 and 
online Tables 1-2 in Study I. CVD mortality was approximately constant up to a BMI of 28 kg/m
2
 
and then increased gradually in both men and women. The graded relationship between BMI and 
CVD mortality did not change substantially after exclusion of deaths occurring during the first five-
year follow-up, or after a competing risk analysis performed in the presence of competing risk of 
cancer mortality. The smoking-BMI interaction was significant for CVD mortality in both men and 
women, and CVD mortality increased gradually at the upper BMI distribution, independent of 
smoking status (see Table 3 in Study I). There was no substantial heterogeneity observed among 
these studies (Figure 2, unpublished results in Study I).  
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Table 4 Baseline characteristics of participants in studies I, III and IV according to cardiovascular disease mortality* 
 
Study I 
 
Studies III and IV 
Cardiovascular disease deaths Cardiovascular disease deaths 
No Yes No Yes 
Men      
Number 63 772 9175  23 615 1071 
Age (years) 48.0 (47.9-48.1) 53.5 (53.3-53.8)†  49.5 (49.3-49.7) 61.1 (60.1-62.0)† 
BMI (kg/m
2
) 25.8 (25.8-25.8) 26.4 (26.3-26.5)†  26.3 (26.3-26.4) 27.2 (27.0-27.5)† 
WC (cm) - -  92.6 (92.4-92.7) 96.0 (95.3-96.6)† 
WHtR - -  0.53 (0.53-0.53) 0.55 (0.55-0.56)† 
WHR - -  0.93 (0.93-0.93) 0.94 (0.94-0.94)† 
ABSI (m
11/6
 kg
-2/3
) - -  
0.0791 (0.0790-
0.0791) 
0.0805 (0.0803-
0.0808)† 
WHHR (m
-1
) - -  0.53 (0.53-0.53) 0.54 (0.54-0.54)† 
Leisure-time physically inactive, % - -  18.7 30.4† 
Smoking status, %      
 Former smokers 24.1 24.1  31.2 31.9 
 Current smokers 37.0 52.2†  23.9 37.0† 
Women      
Number 58 471 4327  21 626 339 
Age (years) 48.1 (48.0-48.1) 56.0 (55.7-56.4)†  47.3 (47.1-47.5) 61.4 (59.3-63.6)† 
BMI (kg/m
2
) 25.8 (25.7-25.8) 27.4 (27.3-27.5)†  26.2 (26.1-26.2) 27.7 (27.2-28.2)† 
WC (cm) - -  81.9 (81.8-82.1) 86.2 (85.0-87.5)† 
WHtR - -  0.51 (0.51-0.51) 0.54 (0.53-0.55)† 
WHR - -  0.81 (0.81-0.81) 0.83 (0.82-0.84)† 
ABSI (m
11/6
 kg
-2/3
) - -  
0.0732 (0.0732-
0.0733) 
0.0748 (0.0742-
0.0753)† 
WHHR (m
-1
) - -  0.50 (0.50-0.50) 0.52 (0.51-0.52)† 
Leisure-time physically inactive, % - -  23.8 43.7† 
Smoking status, %      
 Former smokers 12.8 5.1  18.2 11.2 
 Current smokers 22.9 22.6†  19.1 24.2† 
Abbreviations: BMI, body mass index; WC, waist circumference; WHtR, waist-to-height ratio; WHR, waist-to-hip ratio; ABSI, A Body Shape Index; WHHR, 
waist-to-hip-to-height ratio.  
*Data are age-adjusted means (95% confidence intervals) or as noted.  
†P <0.05 for the difference between no and yes.  
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Figure 2 a 
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Figure 2 Forest plot (random-effects model) of individual studies assessing the hazard ratio for 
cardiovascular disease (CVD) mortality corresponding to a one-unit increment of body mass index 
(BMI) in men (a) and women (b, Study I), using the same methods as shown in Figure 1.   
Figure 2 b 
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Model fitness of parametric and nonparametric modeling (Study III) 
The best-fitting conventional model was a conventional polynomial model for BMI with CVD 
mortality in both sexes (p <0.05 for LRT and for deviance difference test against a conventional 
linear model), which suggests a nonlinear relationship (see online Table 1 in Study III). However, 
the best-fitting conventional model was observed as a conventional linear model for anthropometric 
measures of abdominal obesity with CVD mortality, of which model fitness was not significantly 
improved by a conventional polynomial model (p ≥0.05 for LRT or for deviance difference test 
against a conventional linear model), which indicates a linear relationship. The relationships 
detected by parametric conventional modeling were further supported by nonparametric modeling 
without considerable difference between the best conventional and spline models (AIC difference 
<4).  
Relationship between anthropometric measures of obesity and CVD mortality by spline 
regression model (Study III) 
HR for BMI with CVD mortality in both sexes decreased first at the lower, then increased gradually 
at the middle, and increased more at the upper distributions, which indicates a J-shaped relationship 
with two potential thresholds (see Figures 1 a and g in Study III). HR for anthropometric measures 
of abdominal obesity (WC, WHtR, WHR, ABSI and WHHR) with CVD mortality in both sexes 
increased positively with increasing levels (see Figures 1 b-f and h-l in Study III).  
Threshold of anthropometric measures of obesity in relation to CVD mortality (Study III) 
Threshold values corresponding to a steeper increase in CVD mortality were detected at 29.29 and 
31.98 kg/m
2
 for BMI, 96.4 and 93.3 cm for WC, 0.57 and 0.60 for WHtR, 0.0848 and 0.0813 m
11/6
 
kg
-2/3
 for ABSI in men and women, respectively (see Figure 1 in Study III).  
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5.3 Natural relationship between BMI and cancer mortality (Study I) 
Baseline characteristics of the cohorts and the follow-up data are presented in Table 1 in Study I. 
Old age, current smoking was associated with cancer mortality in both sexes (Table 5). Mean BMI 
was not significantly higher in individuals who died of cancers compared with those who were still 
alive.  
Table 5 Baseline characteristics of participants by cancer mortality (Study I) 
 
Men 
 
Women 
Cancer deaths Cancer deaths 
No Yes No Yes 
Number (%) 65 823 (92.2) 5536 (7.8)  57 956 (94.7) 3212 (5.3) 
Age (years) 48 (0.04) 53 (0.13)*  48 (0.05) 53 (0.17)* 
Current smokers (%) 24 968 (37.9) 3104 (56.1)*  13 349 (23.0) 985 (30.7)* 
Body mass index (kg/m
2)† 25.8 (0.03)* 25.2 (0.12)  25.6 (0.04) 25.5 (0.18) 
*P <0.05 for differences between cancer deaths or not (Yes and No).  
†Data are age-adjusted mean (standard error).  
Relationship between categorical BMI and cancer mortality (Study I) 
Crude mortality rates per 1000 person-years and HRs (95% CI) for cancer mortality corresponding 
to a one-unit increase in BMI adjusted for age, cohort and smoking status are shown in Figure 1 and 
online Tables 1-2 in Study I. BMI had a U-shaped relationship with cancer mortality (see Figure 1 
in Study I). The U-shaped relationship did not change substantially after exclusion of deaths 
occurring during the first five-year follow-up, or after a competing risk analysis performed in the 
presence of competing risk of CVD mortality. The smoking-BMI interaction was significant for 
cancer mortality in both men and women, and the U-shaped relationship disappeared among non-
smokers, which showed no association (see Table 3 in Study I). There was no substantial 
heterogeneity observed among these studies (Figure 3, unpublished results in Study I).  
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Figure 3 a 
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Figure 3 Forest plot (random-effects model) of individual studies assessing the hazard ratio for cancer 
mortality corresponding to a one-unit increment of body mass index (BMI) in men (a) and women (b, 
Study I), using the same methods as shown in Figure 1.  
 
Figure 3 b 
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5.4 Natural relationship between BMI and incidence of cancer (Study 
II) 
Baseline characteristics of the cohorts and the follow-up data in FINRISK study is shown in Table 1 
in Study II. The mean BMI was higher in older individuals, and people with a low BMI tended to be 
smokers (p <0.05), physically active and more educated (p <0.05 for trend test, see Table 2 in Study 
II). People with a low BMI tended to be more in early surveys in men but not in women. Over a 
mean follow-up of 20.6 years, 8429 incident cancers were recorded, 4208 (49.9%) in men.  
Model fitness of parametric and nonparametric modeling 
Table 6 shows that the best-fitting conventional model was a conventional linear model for BMI in 
relation to incidence of cancers of the colon, liver and kidney in men and the gallbladder and breast 
in women (all p <0.05 for LRT against their basic model), as well as the bladder and all sites 
combined in men and the stomach, colon, lung and ovary in women (all p ≥0.05 for LRT against 
their basic model), and the conventional polynomial model did not significantly improve the model 
fitness (p ≥0.05 for LRT or for deviance difference test against their conventional linear model), 
which suggests a linear relationship. To the contrary, the conventional polynomial model 
significantly improved the model fitness of incidence of cancers of the lung in men (all p <0.05 for 
LRT or deviance difference test of against the conventional linear model), the prostate in men as 
well as all sites combined in women (p <0.05 for LRT of quadratic polynomial model and p <0.05 
for deviance difference test of second-order fractional polynomial model against their basic model), 
which suggests a nonlinear relationship (Table 7). Model fitness for incidence of cancers of other 
sites was not improved with any term of BMI added, and a sensitivity analysis that excluded the 
first 5 years of follow-up did not alter the main results (see online Resource 4 in Study II).  
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Table 6 Akaike’s information criterion (degrees of freedom) for the relationship between body mass index (BMI) and hazard risk of 
cancer incidence in men and women (Study II)  
 
Abbreviations: M =1 or 2, a first- or second-order of fractional polynomial; p1 or p2, power of BMI.  
*P <0.05 for likelihood ratio test comparing to other models including basic model (without any term of BMI), conventional linear model (linear term of 
BMI), quadratic polynomial model (linear and centered quadratic term of BMI), or cubic polynomial model (linear, centered quadratic and centered cubic term 
of BMI) adjusting for baseline smoking status, leisure-time physical activity, education and area.  
  
Cancer site Cases Basic model 
Conventional linear 
model 
Conventional polynomial model 
Quadratic Cubic Fractional (M=1) Fractional (M=2) 
Men        
Colon 184 3305.6 (11) 3302.6 (12)* 3304.6 (13) 3306.3 (14) 3302.6 (12) (p=1) 3304.4 (13) (p1=3, p2=3) 
Liver 53 929.5 (10) 923.1 (11)* 925.0 (12) 926.9 (13) 923.1 (11) (p=1) 924.9 (12) (p1=3, p2=3) 
Kidney 107 1953.6 (11) 1944.5 (12)* 1946.5 (13) 1948.3 (14) 1944.5 (12) (p=1) 1946.1(13) (p1=-2, p2=-2) 
Bladder 192 3371.3 (11) 3369.4 (12) 3367.2 (13) 3368.3 (14) 3367.6 (12) (p=-2) 3366.5 (13) (p1=3, p2=3) 
All sites 
combined 
4208 
74 943.5 
(11) 
74 943.9 (12) 
74 945.3 
(13) 
74 946.9 
(14) 
74 943.5 (12) (p=3) 
74 945.1 (13) (p1=-2, 
p2=0) 
Women        
Stomach 120 2132.5 (10) 2132.6 (11) 2131.4 (12) 2132.7 (13) 
2132.2 (11) (p=-
0.5) 
2130.4 (12) (p1=3, p2=3) 
Colon 203 3651.3 (10) 3649.9 (11) 3653.1 (12) 3653.0 (13) 3649.2 (11) (p=3) 3651.0 (12) (p1=-2, p2=3) 
Gallbladder 50 899.6 (9) 896.1 (10)* 898.1 (11) 898.6 (12) 896.1 (10) (p=0.5) 897.6 (11) (p1=-2, p2=-2) 
Lung 114 1922.0 (11) 1920.4 (12) 1919.2 (13) 1920.9 (14) 1919.4 (12) (p=-2) 1918.9 (13) (p1=2, p2=3) 
Breast 1086 
20 244.7 
(11) 
20 239.8 (12)* 
20 241.2 
(13) 
20 237.5 
(14) 
20 237.8 (12) (p=-
2) 
20 239.2(13) (p1=-2, p2=-
2) 
Ovary 205 3829.5 (11) 3829.0 (12) 3830.9 (13) 3832.7 (14) 3828.9 (12) (p=3) 3830.7 (13) (p1=-2, p2=3) 
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Table 7 Akaike’s information criterion (degrees of freedom) for the relationship between body mass index (BMI) and hazard risk of 
cancer incidence in men and women (Study II)  
 
Abbreviations: M =1 or 2, a first- or second-order of fractional polynomial; p1 or p2, power of BMI.  
*P <0.05 for likelihood ratio test comparing to other models including basic model (without any term of BMI), conventional linear model (linear term of 
BMI), quadratic polynomial model (linear and centered quadratic term of BMI), or cubic polynomial model (linear, centered quadratic and centered cubic term 
of BMI) adjusting for baseline smoking status, leisure-time physical activity, education and area.  
†P <0.05 of deviance difference test for first- or second-order fractional polynomial model against the conventional linear model, adjusting for baseline 
smoking status, leisure-time physical activity and area.  
  
Cancer site Cases Basic model 
Conventional linear 
model 
Conventional polynomial model 
Quadratic Cubic Fractional (M=1) Fractional (M=2) 
Men        
Lung 626 
10 574.2 
(11) 
10 556.9 (12)* 
10 554.1 
(13)* 
10 552.3 
(14)* 
10 551.1 (12) (p=-
2)† 
10 551.0 (13) (p1=-2, p2=-
2)† 
Prostate 929 
16 287.6 
(11) 
16 288.8 (12) 
16 284.5 
(13)* 
16 285.2 (14) 16 286.8 (12) (p=-2) 
16 281.5 (13) (p1=-2, p2=-
2)† 
Women        
All sites 
combined 
4221 
77 124.0 
(11) 
77 125.8 (12) 
77 121.3 
(13)* 
77 122.5 (14) 77 124.6 (12) (p=3) 
77 120.3 (13) (p1=3, 
p2=3)† 
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Relationship between BMI and incidence of cancer by spline regression model 
Spline regression analysis showed that BMI had a linear positive association with no threshold with 
incidence of cancers of the colon, liver, kidney, bladder and all sites combined in men (see Figures 
1c, g, s, u and w in Study II), and of cancers of the stomach, colon, gallbladder and ovary in women 
(see Figures 1b, d, j and q in Study II). BMI had an inverse association with incidence of cancers of 
the lung in men (see Figure 1m) and the lung and breast in women (see Figures 1 n and o in Study 
II), whereas a J-shaped association with incidence of all cancers combined in women (Figure 1x in 
Study II), which indicates that there might be thresholds existing. No association was observed for 
BMI and incidence of cancers of prostate or other sites (see Figure 1 in Study II). The relationship 
between BMI and incidence of cancer was basically confirmed by the results from analyses using 
the Cox proportional hazards model, presented as HR (95% CI) for categorical BMI (see online 
Resource 2 in Study II). The interaction between linear BMI and smoking status was significant for 
incidence of all cancers combined in women (p =0.01). High BMI in women was associated with an 
increased overall cancer risk in never smokers but a reduced risk in smokers (see online Resource 3 
in Study II).  
Threshold of BMI in relation to incidence of cancer 
Threshold values corresponding to a steeper increase in incidence of cancer were detected at a BMI 
of 25.49 kg/m
2
 for lung cancer in men, of 24.94 kg/m
2
 for breast cancer in women, and of 24.43 and 
28.54 kg/m
2
 for all cancers combined in women (see Figure 1 in Study II).  
  
53 
 
5.5 Comparison of strengths of different anthropometric measures of 
obesity in relation to CVD mortality (Study IV)  
Baseline characteristics of the cohorts and the follow-up data are presented in Table 2. Table 4 
shows that old age, high distribution of anthropometric measures of obesity and leisure-time 
physical inactivity were significantly associated with CVD mortality. When controlling for baseline 
age and cohort, most anthropometric measures of obesity exhibited significant correlations with 
each other (Pearson’s partial correlation coefficients 0.47–0.96, except for weak positive correlation 
between ABSI and BMI, 0.15 and 0.11 for men and women, respectively, Table 8, unpublished 
results in Study IV).  
Table 8 Pearson’s partial correlation coefficients between anthropometric indicators adjusted 
for baseline age and cohort (Study IV)* 
 BMI WC WHR WSR ABSI WHHR 
Men       
 BMI 1.00 0.88 0.62 0.89 0.15 0.56 
 WC 0.88 1.00 0.80 0.94 0.56 0.61 
 WHR 0.62 0.80 1.00 0.80 0.66 0.88 
 WSR 0.89 0.94 0.80 1.00 0.54 0.78 
 ABSI 0.15 0.56 0.66 0.54 1.00 0.55 
 WHHR 0.56 0.61 0.88 0.78 0.55 1.00 
Women       
 BMI 1.00 0.85 0.47 0.87 0.11 0.48 
 WC 0.85 1.00 0.78 0.96 0.59 0.68 
 WHR 0.47 0.78 1.00 0.77 0.78 0.92 
 WSR 0.87 0.96 0.77 1.00 0.57 0.78 
 ABSI 0.11 0.59 0.78 0.57 1.00 0.69 
 WHHR 0.48 0.68 0.92 0.78 0.69 1.00 
Abbreviations: BMI, body mass index; WC, waist circumference; WHR, waist-to-hip ratio; WSR, waist-to-
stature ratio; ABSI, A Body Shape Index; WHHR, waist-to-hip-to-height ratio.  
*P <0.001 for all indicators.  
  A one-standard-deviation increase in all obesity indicators were significantly associated with a 
more than 19% increase in CVD mortality risk in both men ad women (see Table 3 in Study IV). 
The prediction for CVD mortality was stronger with anthropometric measures of abdominal obesity 
than with BMI or ABSI (p <0.05 for all paired homogeneity tests). WSR/WHtR appeared to be the 
strongest predictor among all the indicators, with a linear positive relationship with CVD mortality 
in both men and women. The main results remained when analyses were performed after the first 5 
years of follow-up were excluded (see Table 3 in Study IV). The increased risk of CVD mortality in 
relation to anthropometric measures of abdominal obesity was independent of BMI levels (see 
Table 4 in Study IV).   
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5.6 Sex differences between obesity and CVD mortality (Study V)  
Table 2 provides baseline characteristics of the cohorts and the follow-up data. Lean women were 
younger, more abdominally obese and had a low prevalence of diabetes, while obese women were 
older, less abdominally obese and had a higher prevalence of diabetes at baseline, compared with 
their male counterparts (see Table 2 in Study V). More men than women were smokers and 
physically active. Men tended to have higher mean values of systolic blood pressure and FPG, and a 
worse lipid profile than women, regardless of BMI categories. Similar sex-differences were 
observed among non-diabetic individuals (see online Table S1 in Study V). Diabetic men tended to 
be older and less physically active than diabetic women. Similar sex-differences were observed for 
the categories of abdominal obesity defined by sex-specific quartiles of WC, WHR and WHtR (see 
online Table S2 in Study V).  
  During the median follow-up of 7.9 years, 945 (4.0%) men and 339 (1.5%) women died from 
CVD. Absolute rates and age-adjusted and multivariate-adjusted HRs for CVD mortality are shown 
across BMI categories or sex-specific quartiles of anthropometric measures of abdominal obesity 
(see Table 3 in Study V). Men had higher CVD mortality rates and higher hazard ratios across BMI 
categories, and categories of abdominal obesity than women, but the sex difference tended to be 
attenuated in the obese categories. For CVD mortality, the interaction was statistically significant 
between sex and WC (p =0.02), and WHtR (p =0.01), but not significant with BMI and WHR. For 
most studies, study-specific HRs were within 10% of the pooled estimate, although there was 
evidence of heterogeneity among studies (I
2
 =95.5%, p <0.05, see online Table S3 in Study V). 
However, exclusion of any study from the analysis had little overall influence on the main results 
(see online Table S4 in Study V). The findings persisted when the analysis was restricted to 
individuals with the first five years of follow-up excluded, or without baseline diabetes, but the sex-
obesity interaction was no longer significant (see Table 4 in Study V). The sex difference among 
people with baseline diabetes diminished especially in the non-obese categories.  
  The findings for BMI categories were not substantially altered when the analysis was repeated 
with additional adjusting for anthropometric measures of abdominal obesity (see online Table S5 in 
Study V). Multivariate adjustment for other CVD risk factors such as systolic blood pressure, FPG, 
TG, HDL-C and Total-C decreased the HRs in each obesity category for both men and women but 
the sex difference remained unchanged (see online Table S6 in Study V).  
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6 DISCUSSION  
6.1 Summary of main findings  
BMI, WC and WHtR showed J-shaped associations with all-cause mortality (Studies I and III), 
whereas WHR, ABSI and WHHR demonstrated positive linear associations (Study III). BMI had a 
J- or U-shaped relationship with CVD mortality (Studies I and III), whereas anthropometric 
measures of abdominal obesity (WC, WHR, WHtR and WHHR) had a linear positive association 
(Study III). The U-shaped association between BMI and cancer mortality was not seen among non-
smokers (Study I). Elevated BMI was significantly associated with higher risk of incidence of 
cancer of certain sites (Study II). High BMI in women was associated with an increased overall 
cancer risk in never smokers but a reduced risk in smokers (Study II). Anthropometric measures of 
abdominal obesity (WC, WHR, WSR/WHtR and WHHR) predicted CVD mortality better than 
BMI did (Study IV). Men had a higher CVD mortality than women in both obese and non-obese 
groups, but this sex difference diminished somewhat in obese individuals (Study V).  
  
56 
 
6.2 Fat accumulation and distribution in relation to CVD mortality 
This study showed that both general obesity and abdominal obesity were significantly positively 
associated with an increased risk of CVD mortality. In addition to excessive fat accumulation, 
abnormal fat distribution might also contribute to the risk of CVD mortality. The threshold values, 
at which a steeper increase in CVD mortality was observed, may have important clinical 
implications in the context of definition of obesity based on clinical outcomes of CVD mortality.  
Possible explanations  
Obesity might be associated with a variety of cardiometabolic risk factors including hypertension, 
diabetes and dyslipidemia, which subsequently leads to CVD. Obesity might be associated with 
hypertension, through an increment in total blood volume and cardiac output caused by increased 
fat mass (195), abnormal activation of the renin-angiotensin system or the renin-angiotensin-
aldosterone system (196-198), or enhancement of sympathetic nervous system activity (199-206). 
Obesity might be associated with insulin resistance (107,207), or by increasing the level of leptin 
(leptin resistance) (208,209), interleukin-6 (210,211), monocyte chemoattractant protein-1 (MCP-1) 
(212-214), tumor necrosis factor-α (TNF-α) (210,215,216), or glucose through decreased glucose 
uptake or utilization but increased hepatic glucogenesis (196), or by decreasing the level of 
adiponectin (217,218), which subsequently results in diabetes.  
  Obesity might also play an important role in dyslipidemia, through enhancement of hepatic 
synthesis of TG, very low density lipoprotein cholesterol and LDL-C, but inhibiting synthesis of 
HDL-C (210,219-222), which subsequently leads to CVD (223-225). Obesity might also mediate 
atherosclerosis through plasminogen activator inhibitor-1 (PAI-1) (226,227). In Study III, the 
relationship between anthropometric measures of obesity and CVD mortality was not substantially 
altered after additional adjustment for one or more other CVD risk factors, including hypertension, 
diabetes and dyslipidemia.  
  Adipose tissue is also a highly active metabolic and endocrine organ, which expresses and secretes 
a variety of bioactive factors including leptin, adiponectin and other cytokines (149,228) which 
exerts more detrimental effects on CVD and might partly explain the greater contribution of 
anthropometric measures of abdominal obesity to the risk of CVD mortality than BMI. Abdominal 
obesity, in particular, is associated with deficiency of estrogens or testosterone (229,230), although 
the causal link still needs to be established (144,231). Deficiency of estrogens or testosterone has 
been consistently found to be associated with an increased risk of CVD (231,232). Increased leptin 
and decreased adiponectin levels were observed in obese individuals (233,234), but the expression 
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of these cytokines differed between subcutaneous and intra-abdominal fat depots (147,235,236). 
The latter were prone to empty their free fatty acids directly into the portal vein (219), exposing the 
liver to high concentrations of free fatty acids, which might lead to hyperinsulinaemia, dyslipidemia 
or hypertension (237). Thus, intra-abdominal fat is believed to be the main pathogenic fat depot that 
has the clinical relevance to CVD (238), particularly being more metabolically active than adipose 
depots located in the hip, thigh or buttocks (239). Fat could also be stored in other organs called 
ectopic fat depositions, for example, in the liver, skeletal muscle, heart and pancreas (240,241). In 
this regard, several studies have found that ectopic fat and intra-abdominal fat each contributes 
independently to the metabolic complications of abdominal obesity (240,242-244).  
  It appears that people with the same WC would have the same CVD risk regardless of differences 
in height, which is invalid when the percentage of fat are higher for shorter individuals compared 
with taller counterparts given the same BMI (245). Some variations have been reported in the WC 
measurement. This may introduce a bias in absolute values of WC between studies, but less likely 
misclassification of individuals within a single study. A recent systematic review showed that 
variations in anatomic locations of WC measurement failed to influence clinical outcomes regarding 
mortality from all causes and CVD (246).  
Threshold for abdominal obesity 
The threshold values, at which a steeper increase in CVD mortality was observed, may have 
important clinical implications in the context of definition of abdominal obesity based on the 
clinical outcomes of mortality (Study III). Currently, the most often used definitions for abdominal 
obesity among Caucasians are WC of 102 cm and 88 cm (82), or 94 cm and 80 cm (83), or WHR of 
0.95 and 0.80 (82) in men and in women, respectively. These existing cut-off values have, however, 
been determined arbitrarily based on analysis of the trade‐offs between sensitivity and specificity 
for discrimination of diabetes or metabolic syndrome (84). Most of these previous studies were 
cross-sectional (82).   
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6.3 Sex differences in relationship between obesity and CVD mortality  
Men had higher CVD mortality than women across all categories of anthropometric measures of 
obesity. Men tended to have a higher prevalence of abnormal levels of conventional CVD risk 
factors than women, such as hypertension, smoking, diabetes, lipid abnormalities and obesity 
(96,97). There is substantial evidence of sex differences in cardiac autonomic modulation (132-
135), lipid and glucose metabolism (136-139), sex hormones (134,140-144) and cytokines (145-
149), that might partially explain the sex difference in CVD mortality in this study. On average, 
middle-aged women have augmented sympathetic inhibition, higher cardiac vagal tone, higher heart 
rate variability, lower susceptibility to arrhythmias, and more decreased myocardial contractility 
than men (132,133,150), leading to a preponderance of vagal over sympathetic control of cardiac 
function (132-135). Before menopause, middle-aged women generally have lower levels of 
blood pressure, serum Total-C and LDL-C, TG and apolipoprotein B and higher levels of HDL-
C and apolipoprotein A-I than men (136,151-153), although Total-C and LDL-C increase in women 
after menopause (151,152). Men tend to have higher fasting and lower post-challenge insulin levels 
than women (138,247), which is not fully explained by differences in fasting and post-challenge 
glucose levels between sexes (247). Additionally, adult men tend to have a higher prevalence of 
insulin resistance than women (137,139).  
  Sex hormones might play important roles in determining body fat mass and its distribution 
(141,144), exert multiple direct and indirect effects on insulin and glucose homeostasis or on 
cardiovascular physiology (134,140,142,143). Specifically, estrogen increases fat deposition 
whereas testosterone inhibits fat deposition, and accordingly, men tend to have less overall body fat 
than women (144), however, the distribution differs between the sexes. Men tend to have more fat 
in the abdominal region, even among normal weight or non-obese ones, which may be 
predominantly due to the accumulation of more visceral fat in men than in women during puberty 
(248). Women tend to accumulate more subcutaneous fat but less intra-abdominal fat than men 
probably due to the effects of estrogen by preventing androgen effects, with less androgen receptors 
in subcutaneous adipose tissue than in VAT (249,250). Intra-abdominal fat is believed to be the 
main pathogenic fat depot with clinical relevance to CVD (238), particularly being more 
metabolically active than adipose depots located in the hip, thigh or buttocks (239). Clinical studies 
have shown that there is higher intra-abdominal fat accumulation in men than in women for a given 
level of BMI, WC or WHR (251-253). Adult women tend to have a larger hip circumference than 
men (254), and thus have metabolically protective physiology of gluteofemoral subcutaneous fat 
mass, perhaps by trapping excess fatty acids and preventing chronic exposure to elevated lipid 
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levels, or through a beneficial adipokine profile (leptin and adiponectin) (255). It remains unclear 
whether CVD risk differs by site of subcutaneous fat accumulation.  
  Adipose tissue is a highly active metabolic and endocrine organ, which expresses and secretes a 
variety of bioactive factors including leptin, adiponectin and other cytokines (149,228), which 
might also contribute to the sex difference in CVD mortality. Women tend to have higher 
circulating leptin levels and higher adiponectin levels than men (145-148). Hyperleptinemia could 
be a sign of resistance to normal leptin signaling regulating food intake and satiety, which is 
believed to be a non-physiological state that could be associated with increased risks of diabetes, 
hypertension and CVD (233). Additionally, hypoadiponectinemia has been found to be associated 
with increased risks of both diabetes and CVD (256,257).  
  Obesity is associated with increased sympathetic activity and decreased vagal activity (258,259), 
hyperglycemia, insulin resistance (107,209), and is accompanied by chronic low-grade 
inflammation (149,260), hypertension and dyslipidemia (136,261,262), all of which might 
predispose to CVD. Abdominal obesity, in particular, is associated with deficiency of estrogens or 
testosterone (229,230), although the causal link still needs to be established (144,231). Deficiency 
of estrogens or testosterone has been consistently found to be associated with an increased risk of 
CVD (231,232). Increased leptin and decreased adiponectin levels were observed in obese 
individuals (233,234), but expression of these cytokines differed between subcutaneous and intra-
abdominal fat depots (147,235,236).  
  Interestingly, the sex difference in CVD mortality appears to somewhat diminish in obese 
individuals, although misclassification bias between obese and non-obese individuals might occur 
due to sex differences in fat distribution, probably enhanced by disturbances of glucose metabolism. 
Mechanisms of sex differences in CVD mortality with obesity are poorly understood. In this study, 
the attenuation of sex differences in CVD mortality among obese individuals remained after 
adjustment of baseline age or other conventional CVD risk factors, or among non-diabetic 
individuals even when using other measures of abdominal obesity. The interactions of sex with 
anthropometric measures were, however, statistically significant only with WC and WHtR in the 
whole study population and not significant with any of the anthropometric measures in non-diabetic 
individuals, which suggests an effect modification by diabetes. Several studies have shown an 
attenuation of sex differences in CVD risk once individuals getting diabetes (96,98-100,102), 
perhaps as a consequence of diabetes inducing higher levels of inflammatory markers and 
impairment of higher rates of nitric oxide release in women compared with men, resulting in 
reduced protective effects of estrogen on body fat distribution, insulin action, glucose homeostasis 
and substrate metabolism, or a more impaired endothelial function in women (140,154,263). Yet, 
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there could be other potential unknown CVD risk factors clustering in obese women due to their 
older age.  
  So far, most epidemiological studies have been conducted primarily on men, leading to lesser 
prevention and treatment eﬀorts in women (264), since CVD previously has been considered a 
‘male disease’ because of an earlier average debut age in men than in women. Obese European 
women appear to be at a greater risk of psychological dysfunction than obese men probably due to 
increased societal pressures on women to be thin (265). Obese women tend to have left ventricular 
concentric and eccentric hypertrophy, whereas obese men have predominantly concentric 
hypertrophy, the latter probably being more strongly related to CVD mortality than eccentric 
hypertrophy (103).  
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6.4 Association between BMI and cancer outcomes  
BMI and cancer incidence 
This work showed that BMI had a non-threshold linear positive association with incidence of 
cancers of the colon, liver, kidney, bladder and all sites combined in men, and of cancers of the 
stomach, colon, gallbladder and ovary in women, an inverse association with incidence of cancers 
of the lung in men and the lung and breast in women, a J-shaped association with incidence of all 
cancers combined in women. In women, high BMI was associated with an increased overall cancer 
risk in never smokers but a reduced risk in smokers.  
  BMI was positively associated with incidence of colon cancer, but had no association with 
incidence of rectal cancer, which is in line with previous studies (32-37,59-62). Despite the fact that 
liver cancer and gallbladder cancer are relatively rare diseases, this study showed that BMI had a 
positive association with incidence of liver cancer in men and gallbladder cancer in women, which 
is in line with previous studies (33,36,71,73,74,131). Obese patients tend to have non-alcoholic 
fatty liver disease or gallstones, which might mediate carcinogenesis (74,266-269). In line with 
previous studies (11,36,42-44), this study showed that BMI was positively associated with 
incidence of kidney cancer in men, which may be due to promoting kidney damage through 
oxidative stress (270), diabetes or hypertension (271,272), or altered circulating concentrations of 
hormones (273,274). In this study, a non-significant linear positive association was observed 
between BMI and incidence of cancers of other sites including the bladder in men and the stomach 
and ovary in women. No association was observed between BMI and incidence of pancreatic cancer 
and cervical cancer. In recent studies, elevated BMI has been linked with an increased risk of 
incidence of cancers of the pancreas (11,33,38-41) and ovary (11,45-48), but the relationship 
between BMI and incidence of stomach cancer (11,36,72), bladder cancer (11,33,36,75,76) or 
cervical cancer remains controversial (11,33,73).  
  Taken together, excess body fat is associated with elevated insulin production, leading to the 
increase of insulin-like growth factor-I, or the secretion of a variety of cytokines and sex steroids, 
which subsequently stimulates cell proliferation and suppresses apoptosis, or chronic inflammation 
through cytokines and chemokines, including TNF-a, Interleukin-1b (IL-1b), IL-6 and 
chemokines such as MCP-1 and Interleukin 8 (275), and thus has been suggested to play a role 
in carcinogenesis (276-278).  
  As an endocrine organ, visceral adipose tissue has been suggested to play a more important role in 
carcinogenesis than the subcutaneous compartment (277). Since BMI does not accurately differentiate 
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fat mass from muscles, nor visceral fat from subcutaneous fat, it may be somehow misleading to 
use BMI as an index for obesity in relation to cancer incidence (279,280). Thus, investigations on 
body composition or fat distribution in relation to cancer incidence are needed but the feasibility to 
conduct such an observational study is low. This work showed that there was a significant inverse 
association between BMI and incidence of breast cancer in women. A decreasing risk association 
among premenopausal women but an increasing risk association among postmenopausal women 
has been reported in previous studies (11,33,63,66-70). Differences in these associations could be 
related to loss of normal ovarian function with reduced ovarian oestrogens production, by which 
obesity could reduce the tumor promoting effects in premenopausal women (281), but with 
enhanced oestrogen synthesis by adipose tissue that could contribute to an increased risk of breast 
cancer among postmenopausal women (279,282).  
  Elevated BMI was inversely associated with incidence of lung cancer, which is consistent with 
previous studies (11,36,49-51). Further, no significant interaction was detected between BMI and 
smoking status, which still needs to be confirmed for the possible metabolic effects of smoking on 
body weight (283,284). A recent epigenetic study reported that one allele of the fat mass and 
obesity-associated gene that had been linked with elevated BMI, was associated with a decreased 
risk of incidence of lung cancer, independent of smoking or weight loss due to the preclinical 
disease (285).  
  The possible explanation for the no association of BMI with incidence of prostate cancer observed 
in this study might be that although with lower levels of sex hormone-binding globulin (SHBG) 
detected which could be a risk factor for prostate cancer (33,52-58,68), obese men also possess 
lower levels of testosterone, which may exert a protective effect against the adverse effect of lower 
levels of SHBG (53,286). This study does not have information on stage of prostate cancer, but 
some studies have revealed that elevated BMI is associated with an increased risk of incidence of 
high-graded or aggressive prostate cancer (55,57,58), but with a decreased risk of incidence of 
localized or low-graded prostate cancer (56-58), the mutual coupling effect might be compensated.  
BMI and cancer mortality 
BMI had a U-shaped relationship with cancer mortality but disappeared among non-smokers, 
which showed no association. The relationship might be influenced by smoking status or 
improvement of cancer treatment. Further investigations are warranted to study site-specific cancer 
mortality.   
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6.5 Methodological considerations 
AIC, as a decision criterion, is used for informal comparisons of models with differing numbers of 
parameters. In this study, AIC was used to judge the model fitness, the lower the AIC value the 
better the model fitness, with reduction of AIC evaluated by the LRT or a deviance difference test 
(192,193) (Studies II-IV). AIC difference ≥4 was considered to be considerably less supported 
relative to the lowest AIC value between non-nested models (194) (Study III). The shape of 
relationship between anthropometric measures of obesity and health outcomes was explored using 
both parametric models (conventional linear or polynomial models) and nonparametric models (the 
linear or restricted cubic spline regression model) (Studies II and III). Several important approaches 
were applied in our data analysis, including competing risk analysis and particularly paired 
homogeneity test, as one formal test of comparing strengths of different measures, which have not 
been used widely in this research field.  
  Age was used as the time-scale in Studies II-V, instead of follow-up time used in Study I, as many 
statisticians have recommended the use of age as the time-scale for the analysis of epidemiologic 
cohort studies with covariates of interest which were either time-dependent or strongly associated 
with age (287,288). Fat tissue mass increases through middle age and declines in old age (155,156). 
Fat is redistributed among different fat depots over time, especially during and after middle age, 
when fat redistributes from subcutaneous to intra-abdominal visceral depots (156-161). VAT 
accumulation increases more rapidly in women with aging, especially after menopause (141,162), 
despite the higher VAT accumulation in men than in women throughout the life span 
(162,163,249).  
  This study showed the interaction between BMI and smoking on cancer mortality and incidence of 
all cancers combined in women (Study I/II). Smoking is associated with both a lower body weight 
and an increased risk of mortality, and is interrelated with obesity in relation to mortality (16,176-
178). Several recent studies have suggested that cigarette smoking aggravates abdominal obesity 
(164-168), perhaps through simultaneously inhibiting lipoprotein lipase activity and increasing 
cortisol levels (167,168). This study found a reduced visceral fat accumulation in Turkish female 
smokers (169). Several studies have identified cigarette smoking as a risk factor for sarcopenia 
(289-291), which is characterized by a muscle atrophy, along with a reduction in muscle tissue 
quality, a replacement of muscle fibres with fat, an increase in fibrosis, changes in muscle 
metabolism, oxidative stress, and degeneration of the neuromuscular junction and leading to 
progressive loss of muscle function and frailty (292), although the cellular and molecular 
mechanisms leading to smoking-induced muscle breakdown still remains elusive.  
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  Limited evidence indicates that leisure-time physical inactivity might play an intermediate role in 
the relationship of anthropometric measures of abdominal obesity with mortality (186), and weaken, 
but not eliminate, the risk associated with excess weight (176). No significant interaction was 
detected between anthropometric measure of obesity and leisure-time physical activity (Studies II-
V). In addition, no substantial influence was observed when further adjusting for education levels in 
Study II.  
  This study was based on several European population- or occupation-based prospective studies, 
with large sample size, long follow-up, reliable assessment of end-points, and detailed assessment 
of lifestyle variables, thus having sufficient power to investigate the association between 
anthropometric measurements and the risk of mortality (Studies I and III-V). Information on 
incidence of cancers was obtained from the FCR (Study II). The data coverage in the FCR is 
virtually complete, 99% for solid tumours, and the data accuracy is high as previously validated by 
different researchers (190).  
  This study does not have data on changes in anthropometric measurements before the baseline and 
during the follow-up, which makes it impossible to exclude the possibility of ‘reverse causation’ 
(106,187). In particular, this study showed that men who died within the first five years of follow-
up had slightly lower age-adjusted mean values of baseline BMI than other men (Study III). 
Potential benefits of a lower BMI might be offset by the negative effect associated with weight loss. 
The potential influence of reverse causality was checked by excluding the deaths within the first 
five years of follow-up, or excluding the first five years of follow-up, and the results were not 
substantially altered (Studies I and III-V). Similarly, the results were not substantially altered much 
after excluding the first five years of follow-up in Study II.  
  This study does not have precise information on menopausal status and hormone therapies that 
would have been potentially affected the development of female breast cancer (63,66,67,69,70), or 
sex differences in obesity with CVD mortality. In addition, this study does not have information on 
several lifestyles or behaviour factors, for instance, dietary factors or alcohol consumption, which 
might contribute to obesity, and is an independent etiologic factor for several cancers, especially for 
stomach cancer and liver cancer (73,293). There are relatively few cases among never smokers and 
hence cannot rule out the possibility of interactions between smoking and BMI in relation to 
incidence of lung cancer. Our data are based on Caucasian-originated European surveys, and further 
investigations are needed due to differences in constitutions of the causes of death across countries, 
or different percentage of body fat across ethnic groups (294).   
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7 CONCLUSIONS AND FUTURE DIRECTIONS 
This study confirmed the deleterious effect of obesity on mortality from various causes and 
incidence of cancers of certain sites. Anthropometric measures of abdominal obesity (WC, WHR, 
WHtR and WHHR) predicted CVD mortality better than BMI, which may imply a more important 
role of fat distribution than fat accumulation and also an effective obesity prevention strategy. Men 
had higher CVD mortality than women across all categories of anthropometric measures of obesity, 
which further supports the view of higher intra-abdominal fat accumulation in men than in women, 
even in non-obese individuals. The sex difference in CVD mortality was slightly attenuated in 
obese individuals, irrespective of diabetes status. This may indicate that women would gradually 
lose their cardiovascular advantage when they are obese, probably due to a more pronounced 
clustering of CVD risk factors among obese women.  
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